

Margaret Gamalo-Siebers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8343579/publications.pdf>

Version: 2024-02-01

22
papers

266
citations

1040056
9
h-index

996975
15
g-index

22
all docs

22
docs citations

22
times ranked

227
citing authors

#	ARTICLE	IF	CITATIONS
1	Discrete Time Multistate Model With Regime Switching for Modeling COVID-19 Disease Progression and Clinical Outcomes. <i>Statistics in Biopharmaceutical Research</i> , 2022, 14, 52-66.	0.8	5
2	Ensuring exchangeability in <sc>dataâ€¢based</sc> priors for a Bayesian analysis of clinical trials. <i>Pharmaceutical Statistics</i> , 2022, 21, 327-344.	1.3	9
3	Power priors with entropy balancing weights in data augmentation of partially controlled randomized trials. <i>Journal of Biopharmaceutical Statistics</i> , 2022, 32, 4-20.	0.8	4
4	Extrapolation as a Default Strategy in Pediatric Drug Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 883-894.	1.6	9
5	Dynamic incorporation of real world evidence within the framework of adaptive design. <i>Journal of Biopharmaceutical Statistics</i> , 2022, 32, 986-998.	0.8	2
6	Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New Therapies. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 704-716.	1.6	10
7	Networked knowledge, combinatorial creativity, and (statistical) innovation. <i>Journal of Biopharmaceutical Statistics</i> , 2021, 31, 109-112.	0.8	1
8	Bigger and bigger circles - the expanding biopharmaceutical statisticianâ€™s toolbox. <i>Journal of Biopharmaceutical Statistics</i> , 2021, 31, iii-xii.	0.8	0
9	Estimands, Handling of Missing Data and Impact on Assumed Effect Size and Power in Pivotal COVID-19 Treatment Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2021, , 1-22.	0.8	1
10	A year in review: artificial intelligence permeates into mainstream statistics in pharmaceutical product development at a laggard pace. <i>Journal of Biopharmaceutical Statistics</i> , 2021, 31, 1-4.	0.8	3
11	Use of Alternative Designs and Data Sources for Pediatric Trials. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 210-223.	0.8	3
12	Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical Review. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1436-1443.	1.6	14
13	Pediatric Extrapolation in Type 2 Diabetes: Future Implications of a Workshop. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 29-39.	4.7	11
14	Journal of biopharmaceutical statistics editorial. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1-2.	0.8	5
15	Incorporating Innovative Techniques Toward Extrapolation and Efficient Pediatric Drug Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 567-578.	1.6	11
16	Pediatric Age Groups and Approach to Studies. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 584-589.	1.6	25
17	Propensityâ€¢scoreâ€¢based priors for Bayesian augmented control design. <i>Pharmaceutical Statistics</i> , 2019, 18, 223-238.	1.3	34
18	Semi-parametric Bayesian regression for subgroup analysis in clinical trials. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 1024-1042.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Propensity score matched augmented controls in randomized clinical trials: A case study. Pharmaceutical Statistics, 2018, 17, 629-647.	1.3	46
20	Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation. Pharmaceutical Statistics, 2017, 16, 232-249.	1.3	58
21	Flexible shrinkage estimation of subgroup effects through Dirichlet process priors. Journal of Biopharmaceutical Statistics, 2016, 26, 1040-1055.	0.8	12
22	Win ratio approach for analyzing composite <scp>timeâ€toâ€event</scp> endpoint with opposite treatment effects in its components. Pharmaceutical Statistics, 0, , .	1.3	2